In conclusion, the current study confirmed that STC1 promoted the malignant biological behavior of GBM cells through the EMT and NF‐κB pathway, implying STC1 was an attractive target for the development of new therapeutic strategies for GBM. Here, NFKB1 is linked to glioblastoma.